Interview: Achilles Advances Armed With £100m
Executive Summary
After receiving major backing for its strategy of targeting clonal neoantigens, Achilles's CEO tells Scrip that the UK firm's manufacturing prowess gives it an edge over competitors.
You may also be interested in...
Syncona Biotechs Face Up To Trial Delays Over COVID-19
Clinical trials across the board are being impacted by coronavirus and Syncona, the investment powerhouse behind a number of UK cell and gene therapy biotechs, says that its portfolio companies are facing considerable delays.
Finance Watch: Cell And Gene Therapies Buck 2019’s Venture Capital Trend
Private Company Edition: VC deals are surging this year for cell and gene therapy firms, according to ARM’s third quarter report. Also, Vivo Capital and the CF Foundation plan to invest nearly $2bn in health care and life science opportunities, and Akeso completes $150m series D.
UK Biotech Ervaxx Launches With Focus On ‘Dark Antigens’
Melanoma is first target for company developing cancer vaccines and T-cell receptor immunotherapies.
Need a specific report? 1000+ reports available
Buy Reports